NEW YORK, Oct. 19 (GenomeWeb News) - Althea Technologies has received a $100,000 Phase I SBIR grant from the National Cancer Institute to help develop validated, quantitative gene-expression assays for multiple pediatric cancers.
The assays are being translated and validated to high-throughput assays using Althea's eXpress Profiling technology. The platform is a high-throughput PCR-based gene-expression analysis technique that can be used to quantitate the gene expression values of 20-35 genes in a single PCR reaction.
Serving as the basis for the development of the multiplexed PCR assays will be research performed by Javed Khan, an oncologist at the Pediatric Oncology Branch of the NCI.